Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index
  10. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective

Volume 38, Issue 1

Original Article

Impact of Vaccination and Comorbidities on Prognosis of Severe COVID-19 Patients Requiring Hospitalization

Zeynep Tekin-Taş
Affiliations
  • Sincan Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara, Türkiye
https://orcid.org/0000-0001-7232-8863
,
Elif Nur Özbay-Haliloğlu
Affiliations
  • Sincan Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Ankara, Türkiye
https://orcid.org/0000-0003-1449-5799
  • COVID-19
  • prognosis
  • vaccination

Abstract

Objective: COVID-19 vaccines have been among the most critical tools in combating the pandemic. Nevertheless, post-vaccination infections continue to be reported globally. This study aims to investigate the association between vaccination status and prognosis in severe COVID-19 cases requiring hospitalization.
Methods: This retrospective single-center study evaluated patients hospitalized with a diagnosis of COVID-19 between March 1, 2021, and November 30, 2021. Patients were categorized into two groups based on their vaccination status. The groups were compared regarding age, gender, comorbidities, length of hospital stay, need for intensive care, mortality, and laboratory parameters.
Results: A total of 775 patients were included in the study, of whom, 20.1% required intensive care, and 7.4% died. The vaccinated group had a higher proportion of patients with advanced age and at least one comorbid condition, hypertension, diabetes mellitus, chronic obstructive pulmonary disease (COPD), immunosuppression, acute renal failure, chronic kidney disease, and congestive heart failure, compared to the unvaccinated group. However, there was no significant difference between the two groups in terms of intensive care requirements or mortality rates.
Conclusion: The findings of our study indicate that, despite the high efficacy of COVID-19 vaccines, the risk of breakthrough infection persists in patients with advanced age, hypertension, diabetes mellitus, COPD, immunosuppression, acute renal failure, chronic kidney disease, and congestive heart failure. Therefore, additional protective measures may be warranted for these high-risk populations.

Show References

References

  1. WHO coronavirus (COVID-19) dashboard [Internet]. Geneva: World Health Organization. [erişim 13 Ağustos 2024]. https://covid19.who.int/table
  2. Kalligeros M, Shehadeh F, Mylona EK, et al. Clinical outcomes of adult patients hospitalized with COVID-19 after vaccination. Trop Med Infect Dis. 2021;6(4):175. [CrossRef]
  3. Tenforde MW, Self WH, Gaglani M, et al; IVY Network. Effectiveness of mRNA vaccination in preventing COVID-19-associated invasive mechanical ventilation and death – United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(12):459-65. [CrossRef]
  4. Tanriover MD, Doğanay HL, Akova M, et al; CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213-22. Erratum in: Lancet. 2022;399(10323):436. [CrossRef]
  5. Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-16. [CrossRef]
  6. Voysey M, Clemens SAC, Madhi SA, et al; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99-111. Erratum in: Lancet. 2021;397(10269):98. [CrossRef]
  7. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. 2021;325(17):1784-6. [CrossRef]
  8. Müller L, Andrée M, Moskorz W, et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 coronavirus disease 2019 vaccination. Clin Infect Dis. 2021;73(11):2065-72. [CrossRef]
  9. Sun J, Zheng Q, Madhira V, et al; National COVID Cohort Collaborative (N3C) Consortium. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182(2):153-62. [CrossRef]
  10. Havers FP, Pham H, Taylor CA, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US States, January 2021 to April 2022. JAMA Intern Med. 2022;182(10):1071-81. [CrossRef]
  11. Moreno-Perez O, Ribes I, Boix V, et al; On behalf the COVID-19 ALC research group. Hospitalized patients with breakthrough COVID-19: Clinical features and poor outcome predictors. Int J Infect Dis. 2022;118:89-94. [CrossRef]
  12. Bosch W, Cowart JB, Bhakta S, et al. Coronavirus disease 2019 vaccine-breakthrough infections requiring hospitalization in Mayo Clinic Florida through August 2021. Clin Infect Dis. 2022;75(1):e892-4. [CrossRef]
  13. Henkens MTHM, Raafs AG, Verdonschot JAJ, et al; CAPACITY-COVID collaborative consortium. Age is the main determinant of COVID-19 related in-hospital mortality with minimal impact of pre-existing comorbidities, a retrospective cohort study. BMC Geriatr. 2022;22(1):184. [CrossRef]
  14. Ho FK, Petermann-Rocha F, Gray SR, et al. Is older age associated with COVID-19 mortality in the absence of other risk factors? General population cohort study of 470,034 participants. PLoS One. 2020;15(11):e0241824. [CrossRef]
  15. Amanatidou E, Gkiouliava A, Pella E, et al. Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabol Open. 2022;14:100180. [CrossRef]
  16. Smits PD, Gratzl S, Simonov M, et al. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023;41(15):2447-55. [CrossRef]
  17. Munigela A, Sowpati DT, M S, Sasikala M, et al; CCMB COVID-19 Team, AIG Hospitals COVID-19 Vaccine Study Team. Clinical outcomes in individuals hospitalized with SARS-CoV-2 Delta variant (B.1.617.2) who had been vaccinated with Covishield (ChAdOx1) and Covaxin (BBV-152). IJID Reg. 2022;5:104-10. [CrossRef]
  18. Yavuz SŞ, Tunçer G, Altuntaş-Aydın Ö, et al. Comparison of the clinical and laboratory findings and outcomes of hospitalized COVID-19 patients who were either fully vaccinated with coronavac or not: an analytical, cross sectional study. Vaccines (Basel). 2022;10(5):733. [CrossRef]
  19. Gül F, Kasapoğlu US, Sabaz MS, et al. The impact of CoronaVac vaccination on 28-day mortality rate of critically Ill patients with COVID-19 in Türkiye. Balkan Med J. 2023;40(6):435-44. [CrossRef]
  20. Brosh-Nissimov T, Maor Y, Elbaz M, et al. Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. Euro Surveill. 2022;27(20):2101026. [CrossRef]
  21. Valero-Bover D, Monterde D, Carot-Sans G, et al. Is age the most important risk factor in COVID-19 patients? The relevance of comorbidity burden: A retrospective analysis of 10,551 hospitalizations. Clin Epidemiol. 2023;15:811-25. [CrossRef]
  22. Domínguez-Ramírez L, Sosa-Jurado F, Díaz-Sampayo G, et al. Age and comorbidities as risk factors for severe COVID-19 in Mexico, before, during and after massive vaccination. Vaccines (Basel). 2023;11(11):1676. [CrossRef]
  • 31-5
  • Zeynep Tekin-Taş
  • zynptkn88@gmail.com
  • 10.36519/kd.2025.5129
  • October 11, 2024
  • December 19, 2024
  • March 21, 2025

  • Tekin-Taş Z, Özbay-Haliloğlu EN. [Impact of vaccination and comorbidities on prognosis of severe COVID-19 patients requiring hospitalization]. Klimik Derg. 2025;37(4):31-5. Turkish.
  • 71
  • 14
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 38, Issue 1 Volume 37, Issue 4 Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1